Last Updated : April 5, 2024
Details
Generic Name:
etrasimod
Project Status:
Active
Therapeutic Area:
Ulcerative colitis
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Velsipity
Project Line:
Reimbursement Review
Project Number:
SR0795-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 08-Dec-23 |
|---|---|
| Call for patient/clinician input closed | 12-Feb-24 |
| Clarification: - Patient input submission received from Crohn's and Colitis Canada and Gastrointestinal Society | |
| Submission received | 05-Feb-24 |
| Submission accepted | 20-Feb-24 |
| Review initiated | 21-Feb-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 14-May-24 |
| Deadline for sponsors comments | 24-May-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 14-Jun-24 |
| Expert committee meeting (initial) | 26-Jun-24 |
| Draft recommendation issued to sponsor | July 09, 2024 To July 11, 2024 |
| Draft recommendation posted for stakeholder feedback | 19-Jul-24 |
| End of feedback period | 02-Aug-24 |
Last Updated : April 5, 2024